|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM147985501 |
| 003 |
DE-627 |
| 005 |
20231223044606.0 |
| 007 |
tu |
| 008 |
231223s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0493.xml
|
| 035 |
|
|
|a (DE-627)NLM147985501
|
| 035 |
|
|
|a (NLM)15106529
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Avoid the risks of mixed medications. How to minimize dangerous interactions with cardiovascular drugs
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.04.2004
|
| 500 |
|
|
|a Date Revised 30.11.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Anticholesteremic Agents
|2 NLM
|
| 650 |
|
7 |
|a Azetidines
|2 NLM
|
| 650 |
|
7 |
|a Cardiovascular Agents
|2 NLM
|
| 650 |
|
7 |
|a Fluorobenzenes
|2 NLM
|
| 650 |
|
7 |
|a Pyrimidines
|2 NLM
|
| 650 |
|
7 |
|a Sulfonamides
|2 NLM
|
| 650 |
|
7 |
|a Spironolactone
|2 NLM
|
| 650 |
|
7 |
|a 27O7W4T232
|2 NLM
|
| 650 |
|
7 |
|a Eplerenone
|2 NLM
|
| 650 |
|
7 |
|a 6995V82D0B
|2 NLM
|
| 650 |
|
7 |
|a Rosuvastatin Calcium
|2 NLM
|
| 650 |
|
7 |
|a 83MVU38M7Q
|2 NLM
|
| 650 |
|
7 |
|a Ezetimibe
|2 NLM
|
| 650 |
|
7 |
|a EOR26LQQ24
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Heart advisor
|d 1999
|g 6(2003), 11 vom: 03. Nov., Seite 1, 7
|w (DE-627)NLM098274252
|x 1523-9004
|7 nnns
|
| 773 |
1 |
8 |
|g volume:6
|g year:2003
|g number:11
|g day:03
|g month:11
|g pages:1, 7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 6
|j 2003
|e 11
|b 03
|c 11
|h 1, 7
|